发明名称 |
PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS |
摘要 |
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. |
申请公布号 |
US2016136259(A1) |
申请公布日期 |
2016.05.19 |
申请号 |
US201615005950 |
申请日期 |
2016.01.25 |
申请人 |
CureVac AG |
发明人 |
Von Der Mülbe Florian;Hoerr Ingmar;Pascolo Steve |
分类号 |
A61K39/12;A61K48/00;C12N7/00 |
主分类号 |
A61K39/12 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for stimulating an immune response to an ebola virus antigen in a subject comprising administering an effective amount of a pharmaceutical composition comprising a mRNA that encodes an ebola virus antigen to the subject. |
地址 |
Tubingen DE |